AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31284842 — intervention group
Group type: COMPARATOR
Intervention: PrEP services in southern metropolitan areas
Number of subjects: 360
Study 31284842 — intervention group
Group type: COMPARATOR
Intervention: PrEP services in non-southern metropolitan areas
Number of subjects: 360
Study 31284842 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PrEP availability by region
Number of subjects: 360
Study 31284842 — intervention group
Group type: COMPARATOR
Intervention: Total number of FQHCs in southern metropolitan areas
Number of subjects: 360
Study 28686771 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin-BP 3.75% aqueous gel, once-daily for 12 weeks
Number of subjects: 20
Study 28686771 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin-BP 3.75% aqueous gel, continued treatment for a further 12 weeks for patients with ≥50% reduction in total lesion count
Number of subjects: 20
Study 28686771 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin-BP 3.75% aqueous gel
Number of subjects: 20
Study 25644134 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable partial dentures (RPD)
Number of subjects: 0
Study 25644134 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened dental arch (SDA)
Number of subjects: 0
Study 25644134 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 23400620 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (152 mg/d vitamin C and 50 mg/d vitamin E)
Number of subjects: 14
Study 23400620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 20849805 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 42
Study 20849805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 17522594 — intervention group
Group type: EXPERIMENTAL
Intervention: BE1 +9/+9 genotype in white Americans
Number of subjects: 228
Study 17522594 — intervention group
Group type: EXPERIMENTAL
Intervention: BE1 +9/-9 genotype in white Americans
Number of subjects: 228
Study 17522594 — intervention group
Group type: COMPARATOR
Intervention: BE1 -9/-9 genotype in white Americans
Number of subjects: 228
Study 17522594 — intervention group
Group type: EXPERIMENTAL
Intervention: BE1 +9/+9 genotype in black Americans
Number of subjects: 228
Study 17522594 — intervention group
Group type: COMPARATOR
Intervention: BE1 +9/-9 and -9/-9 genotypes in black Americans
Number of subjects: 228
Study 16565956 — intervention group
Group type: EXPERIMENTAL
Intervention: VBMCP and recombinant interferon alfa‐2 (INFalpha‐2)
Number of subjects: 653
Study 16565956 — intervention group
Group type: COMPARATOR
Intervention: VBMCP alone
Number of subjects: 653
Study 16565956 — intervention group
Group type: EXPERIMENTAL
Intervention: VBMCP and high‐dose cyclophosphamide
Number of subjects: 653
Study 16565956 — intervention group
Group type: EXPERIMENTAL
Intervention: All eligible patients
Number of subjects: 653
Study 16565956 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who achieved a CR
Number of subjects: 653
Study 16565956 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a partial response
Number of subjects: 653
Study 16565956 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in CR with nonclonal disease
Number of subjects: 653
Study 16565956 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in CR with persistent clonal disease
Number of subjects: 653
Study 14693058 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX) 3.5 g/m(2) intravenously plus rhG-CSF 5 microg x kg(‐1) x day(‐1)
Number of subjects: 52
Study 14693058 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (VP-16) 1000 mg/m(2) or 1500 mg/m(2) intravenously plus rhG-CSF 5 microg x kg(‐1) x day(‐1)
Number of subjects: 52
Study 11075314 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (2 mg every 12 hours)
Number of subjects: 16
Study 11075314 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg every 12 hours)
Number of subjects: 16
Study 11075314 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rosiglitazone and metformin
Number of subjects: 16
Study 11075314 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone and metformin (alone or in combination)
Number of subjects: 16
Study 9345020 — intervention group
Group type: EXPERIMENTAL
Intervention: SCF plus G‐CSF
Number of subjects: 62
Study 9345020 — intervention group
Group type: EXPERIMENTAL
Intervention: SCF pretreatment followed by SCF plus G‐CSF
Number of subjects: 62
Study 9345020 — intervention group
Group type: COMPARATOR
Intervention: SCF pretreatment
Number of subjects: 62
Study 9345020 — intervention group
Group type: COMPARATOR
Intervention: Control (G‐CSF alone)
Number of subjects: 62
Study 8177925 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (2.9, 4.8, and 9.6 g Nootropil UCB)
Number of subjects: 5
Study 8177925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 3516510 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 100 mg
Number of subjects: 7
Study 3516510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 29747232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 149
Study 29747232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 27097693 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional chloroquine
Number of subjects: 86
Study 27097693 — intervention group
Group type: COMPARATOR
Intervention: Oral chloroquine
Number of subjects: 86
Study 25230076 — intervention group
Group type: EXPERIMENTAL
Intervention: Air Optix Aqua Multifocal (AOAM)
Number of subjects: 28
Study 25230076 — intervention group
Group type: EXPERIMENTAL
Intervention: PureVision Multifocal (PM)
Number of subjects: 28
Study 25230076 — intervention group
Group type: COMPARATOR
Intervention: Monofocal contact lenses (Air Optix Aqua)
Number of subjects: 28
Study 25230076 — intervention group
Group type: EXPERIMENTAL
Intervention: AOAM and PM
Number of subjects: 28
Study 25230076 — intervention group
Group type: EXPERIMENTAL
Intervention: All contact lenses
Number of subjects: 28
Study 24351534 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (0.3 g/kg protein in the form of glutamine dipeptide for 10 days)
Number of subjects: 60
Study 24351534 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine combined with ulinastatin (0.3 g/kg protein in the form of glutamine dipeptide for 10 days + intravenous injection of 100 kU ulinastatin every 8 hours for 7 days)
Number of subjects: 60
Study 24351534 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 60
Study 20022651 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose treatment
Number of subjects: 0
Study 18156400 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 g/d DHA oil (3 g DHA/d)
Number of subjects: 100
Study 18156400 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 100
Study 15665711 — intervention group
Group type: EXPERIMENTAL
Intervention: MCV-4
Number of subjects: 1398
Study 15665711 — intervention group
Group type: COMPARATOR
Intervention: PSV-4
Number of subjects: 1398
Study 12620949 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI) with 0.15 mL x kg(‐1) x hr(‐1) 0.2% ropivacaine
Number of subjects: 28
Study 12620949 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) with 5 mL single bolus application of R or BS every 20 min
Number of subjects: 28
Study 12620949 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA with R
Number of subjects: 28
Study 12620949 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA
Number of subjects: 28
Study 12620949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine plasma concentrations after PCEA
Number of subjects: 28
Study 10846377 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial Discussions condition (jurors permitted to discuss evidence)
Number of subjects: 0
Study 10846377 — intervention group
Group type: COMPARATOR
Intervention: No Discussions condition (jurors prohibited from discussing evidence)
Number of subjects: 0
Study 10846377 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial Discussions condition
Number of subjects: 0
Study 9359638 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 207
Study 9359638 — intervention group
Group type: COMPARATOR
Intervention: Direct intraperitoneal insemination (DIPI)
Number of subjects: 207
Study 1345040 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental gown
Number of subjects: 147
Study 1345040 — intervention group
Group type: COMPARATOR
Intervention: Standard drape
Number of subjects: 147
Study 4004977 — intervention group
Group type: COMPARATOR
Intervention: Self-help education program for arthritis patients
Number of subjects: 0
Study 28266704 — intervention group
Group type: EXPERIMENTAL
Intervention: EO/LP solution (Australian eucalyptus oil and Leptospermum petersonii); applied thrice with 7-day intervals
Number of subjects: 0
Study 28266704 — intervention group
Group type: EXPERIMENTAL
Intervention: EO/LP solution (Australian eucalyptus oil and Leptospermum petersonii); single application
Number of subjects: 0
Study 28266704 — intervention group
Group type: COMPARATOR
Intervention: P/PB mousse (pyrethrins and piperonyl butoxide); applied twice with a 7-day interval
Number of subjects: 0
Study 27707940 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CH)
Number of subjects: 6095
Study 27707940 — intervention group
Group type: COMPARATOR
Intervention: Iodine Tincture (IT)
Number of subjects: 6095
Study 24655542 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (eight sessions over 4 weeks)
Number of subjects: 76
Study 24655542 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture treatment (after a 4-week waiting period)
Number of subjects: 76
Study 24655542 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 76
Study 22446143 — intervention group
Group type: EXPERIMENTAL
Intervention: paliperidone palmitate
Number of subjects: 97
Study 22446143 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 97
Study 22446143 — intervention group
Group type: COMPARATOR
Intervention: ongoing treatment
Number of subjects: 97
Study 20516443 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 471
Study 20516443 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus bevacizumab (CB)
Number of subjects: 471
Study 20516443 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine, bevacizumab, and mitomycin (CBM)
Number of subjects: 471
Study 20516443 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 471
Study 18929270 — intervention group
Group type: EXPERIMENTAL
Intervention: HGA-S (headgear-activator with stepwise mandibular advancement)
Number of subjects: 3
Study 18929270 — intervention group
Group type: EXPERIMENTAL
Intervention: HGA-M (headgear-activator with maximum jumping of the mandible)
Number of subjects: 3
Study 18929270 — intervention group
Group type: EXPERIMENTAL
Intervention: HGH-S (headgear-Herbst appliance with stepwise advancement)
Number of subjects: 3
Study 18929270 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (not specified)
Number of subjects: 3
Study 11703953 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 35
Study 11703953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 11703953 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 35
Study 9236651 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management (n = 19)
Number of subjects: 35
Study 9236651 — intervention group
Group type: COMPARATOR
Intervention: Surgical management (n = 16)
Number of subjects: 35
Study 9236651 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 35
Study 9236651 — intervention group
Group type: COMPARATOR
Intervention: Expectant management and Surgical management
Number of subjects: 35
Study 8220862 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine hydrochloride (0.5%) moistened Kaltostat dressing
Number of subjects: 0
Study 8220862 — intervention group
Group type: COMPARATOR
Intervention: Saline moistened Kaltostat dressing
Number of subjects: 0
Study 8220862 — intervention group
Group type: COMPARATOR
Intervention: Dry calcium alginate dressing (Kaltostat Britcair)
Number of subjects: 0
Study 3476513 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rinse containing 300 micrograms/ml sanguinaria extract
Number of subjects: 0
Study 3476513 — intervention group
Group type: EXPERIMENTAL
Intervention: Supragingival irrigation with dilute solutions of sanguinaria (22.5 micrograms/ml and 90 micrograms/ml)
Number of subjects: 0
Study 3476513 — intervention group
Group type: COMPARATOR
Intervention: Placebo oral rinse
Number of subjects: 0
Study 29204811 — intervention group
Group type: EXPERIMENTAL
Intervention: GenomeCOMPASS™ report
Number of subjects: 52
Study 29204811 — intervention group
Group type: COMPARATOR
Intervention: Usual care summary letter
Number of subjects: 52
Study 29204811 — intervention group
Group type: EXPERIMENTAL
Intervention: GenomeCOMPASS™ report (after crossover)
Number of subjects: 52
Study 29142959 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPPO-ST
Number of subjects: 68
Study 29142959 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 68
Study 26354567 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (intervention group)
Number of subjects: 43
Study 26354567 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 43
Study 23602068 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg intravenous methylprednisolone
Number of subjects: 40
Study 23602068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20664583 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 69
Study 20664583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 18416473 — intervention group
Group type: EXPERIMENTAL
Intervention: Current alcohol consumption (defined as more than once of alcohol drinking per month)
Number of subjects: 3953
Study 18416473 — intervention group
Group type: EXPERIMENTAL
Intervention: Current alcohol consumption
Number of subjects: 3953
Study 16798445 — intervention group
Group type: COMPARATOR
Intervention: 0.2% ropivacaine (R-group)
Number of subjects: 198
Study 16798445 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine with fentanyl 2 microg/mL (RF-group)
Number of subjects: 198
Study 12884990 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 10 mg and fentanyl 25 microg (upright for 15 min)
Number of subjects: 30
Study 12884990 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 15 mg (immediately positioned supine)
Number of subjects: 30
Study 10993854 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmokers
Number of subjects: 1432
Study 10993854 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitters
Number of subjects: 1432
Study 10993854 — intervention group
Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 1432
Study 8827897 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin K1 (N = 13)
Number of subjects: 44
Study 8827897 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin K1 (N = 16)
Number of subjects: 44
Study 8827897 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 15)
Number of subjects: 44
Study 8827897 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups at one-month follow-up
Number of subjects: 44
Study 1447916 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental version with a pause before targeted words
Number of subjects: 72
Study 1447916 — intervention group
Group type: COMPARATOR
Intervention: Control version with normal prosody
Number of subjects: 72
Study 1447916 — intervention group
Group type: EXPERIMENTAL
Intervention: CA matched group
Number of subjects: 72
Study 1447916 — intervention group
Group type: EXPERIMENTAL
Intervention: MLU matched group
Number of subjects: 72
Study 31331273 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 27880888 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple hop test (MHT) for CAI subjects
Number of subjects: 51
Study 27880888 — intervention group
Group type: COMPARATOR
Intervention: Uninjured controls
Number of subjects: 51
Study 26365555 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (cholecalciferol) 100,000 IU (2.5 mg) monthly for an estimated median of 3.3 years (range 2.5‐4.2 years)
Number of subjects: 5110
Study 26365555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5110
Study 26365555 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 5110
Study 24462634 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including individual education and one to three additional interventions.
Number of subjects: 11
Study 24462634 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 11
Study 21637099 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator training to automaticity
Number of subjects: 30
Study 21637099 — intervention group
Group type: COMPARATOR
Intervention: Proficiency-based training
Number of subjects: 30
Study 19444661 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress and coping model interventions addressing negative affect, adaptive coping, and social support
Number of subjects: 244
Study 19444661 — intervention group
Group type: COMPARATOR
Intervention: Neuropsychological functioning assessment
Number of subjects: 244
Study 18990064 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexiganan cream (topical antimicrobial peptide)
Number of subjects: 835
Study 18990064 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (oral fluoroquinolone antibiotic)
Number of subjects: 835
Study 15673386 — intervention group
Group type: EXPERIMENTAL
Intervention: Late potential (LP) by signal-averaged ECG (SAECG)
Number of subjects: 46
Study 15673386 — intervention group
Group type: EXPERIMENTAL
Intervention: RMS40
Number of subjects: 46
Study 15673386 — intervention group
Group type: EXPERIMENTAL
Intervention: RMS40 < 15 microV
Number of subjects: 46
Study 15673386 — intervention group
Group type: EXPERIMENTAL
Intervention: LAS40 and fQRSd
Number of subjects: 46
Study 12637463 — intervention group
Group type: EXPERIMENTAL
Intervention: Bexarotene 200 mg/m²/d
Number of subjects: 145
Study 12637463 — intervention group
Group type: EXPERIMENTAL
Intervention: Bexarotene 500 mg/m²/d
Number of subjects: 145
Study 12637463 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen and Bexarotene
Number of subjects: 145
Study 12637463 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 145
Study 10593328 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunonutrition (an arginine‐, RNA‐, and omega3 fatty acid‐supplemented diet) for 5 days preoperatively and enteral feeding for 10 days postoperatively
Number of subjects: 154
Study 10593328 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic control diet (1 L/d) for 5 days preoperatively and enteral feeding for 10 days postoperatively
Number of subjects: 154
Study 8914685 — intervention group
Group type: EXPERIMENTAL
Intervention: InGaAl diode laser (670 nm, 60 mW, appr. 108 J)
Number of subjects: 10
Study 8914685 — intervention group
Group type: COMPARATOR
Intervention: Non-coherent monochromatic light (635 nm, 112.5 mW, appr. 202.5 J)
Number of subjects: 10
Study 8914685 — intervention group
Group type: EXPERIMENTAL
Intervention: He-Ne laser (632.8 nm, 10 mW, total energy appr. 9.4 J)
Number of subjects: 10
Study 1860327 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion at 5 micrograms/kg.min
Number of subjects: 8
Study 1860327 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion at 10 micrograms/kg.min
Number of subjects: 8
Study 1860327 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion at all three rates (2.5, 5, and 10 micrograms/kg.min)
Number of subjects: 8
Study 6839635 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg at bedtime
Number of subjects: 8
Study 6839635 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1200 mg a day
Number of subjects: 8
Study 6839635 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 2400 mg a day
Number of subjects: 8
Study 6839635 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin alone (control)
Number of subjects: 8
Study 30422911 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 861
Study 30422911 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitors (PIs)
Number of subjects: 861
Study 30422911 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside reverse transcriptase inhibitors
Number of subjects: 861
Study 28264870 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Percutaneous Coronary Intervention (PCI) in patients with early Q waves (QW)
Number of subjects: 515
Study 28264870 — intervention group
Group type: COMPARATOR
Intervention: Primary Percutaneous Coronary Intervention (PCI) in patients without early Q waves (non-QW)
Number of subjects: 515
Study 26805558 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 minutes post-infusion scalp cooling
Number of subjects: 134
Study 26805558 — intervention group
Group type: COMPARATOR
Intervention: 45 minutes post-infusion scalp cooling
Number of subjects: 134
Study 26805558 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 134
Study 25375400 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fibroblast-hyaluronic acid complex
Number of subjects: 63
Study 25375400 — intervention group
Group type: COMPARATOR
Intervention: Non-adherent foam dressing (Control)
Number of subjects: 63
Study 22516910 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear periodized resistance training (NLP)
Number of subjects: 30
Study 22516910 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear periodized resistance training (LP)
Number of subjects: 30
Study 22516910 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30